

Resource Summary Report

Generated by PRECISE-TBI on Sep 2, 2026

Phospho-cdc2 (Thr161) Antibody

RRID:AB_2074652

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9114, RRID:AB_2074652

Antibody Information

URL: http://antibodyregistry.org/AB_2074652

Proper Citation: Cell Signaling Technology Cat# 9114, RRID:AB_2074652

Target Antigen: cdc2, phospho (Thr161)

Clonality: unknown

Comments: Applications: W

Antibody Name: Phospho-cdc2 (Thr161) Antibody

Description: This unknown targets cdc2, phospho (Thr161)

Target Organism: rat, mouse, human

Antibody ID: AB_2074652

Vendor: Cell Signaling Technology

Catalog Number: 9114

Record Creation Time: 20231110T044857+0000

Record Last Update: 20260829T145128+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-cdc2 (Thr161) Antibody.

No alerts have been found for Phospho-cdc2 (Thr161) Antibody.

Data and Source Information

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Zhou Y, et al. (2026) ERK1/2 function as a central hub safeguarding primed human embryonic stem cell identity via multifaceted regulatory networks. *Cell reports*, 45(7), 117675.

Xie Y, et al. (2026) QW-5-70 targets the colchicine site and demonstrates antitumor activity in P-gp-overexpressing cancer models. *Molecular cancer therapeutics*, OF1.

Ma J, et al. (2025) Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. *Molecular cancer therapeutics*, 24(8), 1171.

Takacs L, et al. (2025) Evidence of substrate control of Cdk phosphorylation during the budding yeast cell cycle. *Cell reports*, 44(4), 115534.

Guarducci C, et al. (2024) Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1889.

Shintomi K, et al. (2024) Recombinant cyclin B-Cdk1-Suc1 capable of multi-site mitotic phosphorylation in vitro. *PloS one*, 19(3), e0299003.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Wilson GA, et al. (2023) Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition. *Molecular cell*, 83(22), 4078.

Haase J, et al. (2022) The TFIIF complex is required to establish and maintain mitotic chromosome structure. *eLife*, 11.

Branigan TB, et al. (2021) MMB-FOXN1-driven premature mitosis is required for CHK1 inhibitor sensitivity. *Cell reports*, 34(9), 108808.

Olson CM, et al. (2019) Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. *Cell chemical biology*, 26(6), 792.